NVIDIA partners with Novo Nordisk to accelerate drug development using AI
Chip manufacturer NVIDIA announced on Wednesday a partnership with Novo Nordisk to accelerate the Danish pharmaceutical giant's efforts in drug development using artificial intelligence (AI). This collaboration is expected to support an agreement between Novo Nordisk and the Danish AI Innovation Center, which owns and operates Denmark's flagship AI supercomputer, Gefion. As part of the collaboration, the two companies will focus on developing customized AI models for Novo Nordisk researchers to use in the early stages of clinical development and running advanced simulation and physical AI technologies. Rory Kelleher, Senior Director of Business Development for Life Sciences at NVIDIA, stated, "By partnering with Novo Nordisk, we are advancing critical R&D applications with foundational tools that can fully leverage the potential of generative and agent-based AI to improve drug development." NVIDIA announced this news at the GTC event held in Paris, France, where the company also unveiled several key European partners
According to Zhitong Finance APP, chip manufacturer NVIDIA (NVDA.US) announced on Wednesday a collaboration with Novo Nordisk (NVO.US) to accelerate the Danish pharmaceutical giant's efforts in drug development using artificial intelligence (AI).
This partnership is expected to support an agreement reached between Novo Nordisk and the Danish AI Innovation Center, which owns and operates Denmark's flagship AI supercomputer, Gefion.
As part of the collaboration, the two companies will focus on developing customized AI models for Novo Nordisk researchers to use in the early stages of clinical development and running advanced simulation and physical AI technologies.
Rory Kelleher, Senior Director of Business Development for Life Sciences at NVIDIA, stated, "By collaborating with Novo Nordisk, we are advancing critical R&D applications using foundational tools that can fully leverage the potential of generative and agent-based AI to improve drug development."
NVIDIA released this news at the GTC event held in Paris, France, where the company also announced several important European partners
